CT1113

Overview

CT1113 is a selective, orally active USP25/USP28 inhibitor. CT1113 inhibits cancer cell proliferation, induces apoptosis , and causes G2/S phase cell cycle arrest. CT1113 reduces the levels of total BCR-ABL1 , phosphorylated BCR-ABL1, total STAT5 , and phosphorylated STAT5 , but does not alter the mRNA level of BCR-ABL1. CT1113 is applicable to research related to pancreatic cancer , colon cancer , and acute leukemia.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > STAT | Products > Signaling Pathways > c-Myc | Products > Signaling Pathways > Deubiquitinase | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Bcr-Abl

Product Information

• Catalog No.: HY-153996
• CAS No.: 2523435-18-7
• Molecular Formula: C25H29N5O2S
• Molecular Weight: 463.60
• Purity: 99.61%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (10.79 mM); Clear solution
• Availability: In-stock

Source

Original product source